**Annex ZZA**

(informative)

**Relationship between this European standard and the General Safety and Performance Requirements of Regulation (EU) 2017/746 aimed to be covered**

This European standard has been prepared under M/575to provide one voluntary means of conforming to the General Safety and Performance Requirements of Regulation (EU) 2017/746 of 5 April 2017 concerning *in vitro* diagnostic medical devices [OJ L 117] and to system or process requirements including those relating to quality management systems, risk management, post-market surveillance systems, performance studies, clinical evidence or post-market performance follow-up.

Once this standard is cited in the Official Journal of the European Union under that Regulation, compliance with the normative clauses of this standard given in Table ZZA.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding General Safety and Performance Requirements of that Regulation, and associated EFTA regulations.

Where a definition in this standard differs from a definition of the same term set out in Regulation (EU) 2017/746, the differences shall be indicated in the Annex Z . For the purpose of using this standard in support of the requirements set out in Regulation (EU) 2017/746, the definitions set out in this Regulation prevail.

Where the European standard is an adoption of an International Standard, the scope of this standard can differ from the scope of the European Regulation that it supports. As the scope of the applicable regulatory requirements differ from nation to nation and region to region, the standard can only support European regulatory requirements to the extent of the scope of the In Vitro Diagnostic Regulation (EU) 2017/746).

NOTE 1 Where a reference from a clause of this standard to the risk management process is made, the risk management process needs to be in compliance with Regulation (EU) 2017/746. This means that risks have to be ‘reduced as far as possible’, ‘reduced to a level as low as reasonably practicable’, ‘reduced to the lowest possible level’, ‘reduced as far as possible and appropriate’, ‘removed or reduced as far as possible’, ‘eliminated or reduced as far as possible’, ‘prevented’ or ‘minimized’, according to the wording of the corresponding General Safety and Performance Requirement.

NOTE 2 The manufacturer’s policy for determining **acceptable risk** must be in compliance with General Safety and Performance Requirements 1, 2, 3, 4, 5, 8, 10, 11, 13, 15, 16, 17, 18 and 19 of the Regulation.

NOTE 3 When a General Safety and Performance Requirement does not appear in Table ZZA.1, it means that it is not addressed by this European Standard.

**Table ZZA.1 – Correspondence between this European standard and Annex I of Regulation (EU) 2017/746 [OJ L 117]** and to system or process requirements including those relating to quality management systems, risk management, post-market surveillance systems, performance studies, clinical evidence or post-market performance follow-up

|  |  |  |
| --- | --- | --- |
| General Safety and Performance Requirements of Regulation (EU) 2017/746 | Clause(s) / sub-clause(s)of this EN | Remarks / Notes |
| *[Only one GSPR per row]**[Rows ordered according to the numerical order of the GSPRs]* |  | *[To be filled in with any explanations needed to clarify the coverage of the GSPR.]* |
|  |  |  |

[NOTE to the drafter, to be removed before publication:

This table is to be used to declare a detailed correspondence between the GSPR and the clauses/sub-clauses of the standard. Please use as many rows as needed).]

WARNING 1: Presumption of conformity stays valid only as long as a reference to this European standard is maintained in the list published in the Official Journal of the European Union. Users of this standard should consult frequently the latest list published in the Official Journal of the European Union.

WARNING 2: Other Union legislation may be applicable to the product(s) falling within the scope of this standard.

*If required* For devices which are also machinery within the meaning of Article 2(a) of Directive 2006/42/EC on Machinery, in accordance with Article 1(6) of Regulation (EU) 2017/746, the following Table ZZA.2 details the relevant Essential Health and Safety Requirements of Directive 2006/42/EC on Machinery to the extent to which they are more specific than the General Safety and Performance Requirements set out in Chapter II of Annex I of Regulation (EU) 2017/746 along with the corresponding clauses of this European Standard. Table ZZA.2, however, does not imply any citation in the OJEU under the machinery directive and thus does not provide presumption of conformity for the machinery directive.

Where a definition in this standard differs from a definition of the same term set out in Regulation (EU) 2017/746, the differences shall be indicated in the Annex Z. For the purpose of using this standard in support of the requirements set out in Regulation (EU) 2017/746, the definitions set out in this Regulation prevail.

Where the European standard is an adoption of an International Standard, the scope of this standard can differ from the scope of the European Regulation that it supports. As the scope of the applicable regulatory requirements differ from nation to nation and region to region, the standard can only support European regulatory requirements to the extent of the scope of the In Vitro Diagnostic Regulation (EU) 2017/746).

**Table ZZA.2 — Relevant Essential Health and Safety Requirements from Directive 2006/42/EC on machinery that are addressed by this Document (according to article 1, item 6, of Regulation (EU) 2017/746)**

|  |  |  |
| --- | --- | --- |
| Essential Health and Safety Requirements of Directive 2006/42/EC | Clause(s) / sub-clause(s)of this EN | Remarks / Notes |
| *[Only one EHSR per row]**[Rows ordered according to the numerical order of the EHSRs]* |  | *[To be filled in with any explanations needed to clarify the coverage of the EHSR.]* |
|  |  |  |